• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WAN Nanyan, JIANG Cuihua, GAO Meng, ZHANG Jian, YIN Zhiqi, PAN Ke. Paeoniflorin inhibits programmed cell death-1-ligand 1 expression in HepG2 cells by regulating JAK/STAT3 signal pathway[J]. Journal of China Pharmaceutical University, 2019, 50(2): 213-221. DOI: 10.11665/j.issn.1000-5048.20190213
Citation: WAN Nanyan, JIANG Cuihua, GAO Meng, ZHANG Jian, YIN Zhiqi, PAN Ke. Paeoniflorin inhibits programmed cell death-1-ligand 1 expression in HepG2 cells by regulating JAK/STAT3 signal pathway[J]. Journal of China Pharmaceutical University, 2019, 50(2): 213-221. DOI: 10.11665/j.issn.1000-5048.20190213

Paeoniflorin inhibits programmed cell death-1-ligand 1 expression in HepG2 cells by regulating JAK/STAT3 signal pathway

More Information
  • In order to explore the effect and its mechanism of paeoniflorin on PD-L1, a PD-L1 high expression cell model was established in interferon gamma(IFN-γ)-induced HepG2 cells. The cytotoxicity of paeoniflorin was detected by MTT assay. Flow cytometry, ELISA and RT-PCR were performed to detect protein and mRNA levels of PD-L1 regulated by paeoniflorin. In HepG2 cells and Jurkat T cell co-culture system, the expression of IL-2 was detected by ELISA. Besides, T cell proliferation was evaluated by CCK-8 method, and the protein expression levels of PD-L1, JAK and STAT3 after drug treatment were determined by Western blot. These results indicated that paeoniflorin could significantly down-regulate the levels of PD-L1 protein and mRNA. In addition, it increased the number of T cells and the concentration of IL-2 in the co-culture system. Furthermore, paeoniflorin could significantly inhibit the protein expression of JAK and STAT3. Au the above experimental data indicated that paeoniflorin could down-regulate the expression of PD-L1, and its mechanism might be related to the JAK/STAT3 pathway.
  • [1]
    Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].Ca Cancer J Clin,2011,61(2):69-90.
    [2]
    Gao Q,Wang XY,Qiu SJ,et al.Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J].Clin Cancer Res,2009,15(3):971-979.
    [3]
    Zhou J,Liu M,Sun H,et al.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy[J].Gut,2017,67(5):gutjnl-2017-314032.
    [4]
    Dai X,Pi G,Yang SL,et al.Association of PD-L1 and HIF-1α coexpression with poor prognosis in hepatocellular carcinoma[J].Transl Oncol,2018,11(2):559.
    [5]
    Tian JP, Zhang J, Zhou JP, et al. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J].J China Pharm Univ(中国药科大学学报),2019,50(1):1-10.
    [6]
    Sharma P,Allison JP.The future of immune checkpoint therapy[J].Science,2015,348(6230):56.
    [7]
    Zou W,Wolchok JD,Chen L.PD-L1(B7-H1)and PD-1 pathway blockade for cancer therapy:mechanisms,response biomarkers,and combinations[J].Sci Transl Med,2016,8(328):328rv4.
    [8]
    Greten TF,Xin WW,Korangy F.Current concepts of immune based treatments for patients with HCC:from basic science to novel treatment approaches[J].Gut,2015,64(5):842-848.
    [9]
    Naidoo J,Page DB,Li BT,et al.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J].Ann Oncol,2015,26(12):2375-2391.
    [10]
    Zhu H,Bengsch F,Svoronos N,et al.BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression[J].Cell Rep,2016,16(11):2829-2837.
    [11]
    Jiang Z,Yang Y,Yang Y,et al.Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune[J].Biomed Pharmacother,2017,96:378-383.
    [12]
    Kim ID,Ha BJ.Paeoniflorin protects RAW 264.7 macrophages from LPS-induced cytotoxicity and genotoxicity[J].Toxicol In Vitro,2009,23(6):1014-1019.
    [13]
    Liu DF, Wei W, Song LH. Protective effect of paeoniflorin on immunological liver injury induced by bacillus Calmette-Guerin plus lipopolysaccharide:modulation of tumour necrosis factor-alpha and interleukin-6 MRNA[J].Clin Exp Pharmacol Physiol,2010,33(4):332-339.
    [14]
    Lu JT, He W, Song SS, et al. Paeoniflorin inhibited the tumor invasion and metastasis in human hepatocellular carcinoma cells[J].Bratisl Lek Listy,2014,115(7):427-433.
    [15]
    Hung JY,Yang CJ,Tsai YM,et al.Antiproliferative activity of paeoniflorin is through cell cycle arrest and the Fas/Fas ligand-mediated apoptotic pathway in human non-small cell lung cancer A549 cells[J].Clin Exp Pharmacol Physiol,2010,35(2):141-147.
    [16]
    Xu RX,Nie XH,Jia OY,et al.Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway[J].Drug Des Devel Ther,2015,9(default):5611-5622.
    [17]
    Zheng YB,Xiao GC,Tong SL,et al.Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling[J].World J Gastroenterol,2015,21(23):7197-7207.
    [18]
    Zhao MG,Yang HM,Jiang CH,et al.Intervention effects of the triterpenoids from Cyclocarya paliurus on free fatty acids-induced steatosis in HepG2 cells[J].J China Pharm Univ(中国药科大学学报),2018,49(3):333-340.
    [19]
    Wang YT,Zhao MG,Sheng XP,et al.Effect of triterpenic acid-enriched fraction from Cyclocarya paliurus on high glucose-induced pancreatic α cells insulin resistance[J].J China Pharm Univ(中国药科大学学报),2018,49(2):215-221.
    [20]
    Ribas A.Adaptive immune resistance:how cancer protects from immune attack[J].Cancer Discov,2015,5(9):915-919.
    [21]
    Elkhoueiry AB,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492.
    [22]
    Coombs MR, Harrison ME, Hoskin DW. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells[J].Cancer Lett,2016,380(2):424-433.
    [23]
    Hato T,Goyal L,Greten TF,et al.Immune checkpoint blockade in hepatocellular carcinoma:current progress and future directions[J].Hepatology,2014,60(5):1776-1782.
    [24]
    Abiko K,Matsumura N,Hamanishi J,et al.IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J].Br J Cancer,2015,112(9):1501-1509.
    [25]
    Muhlbauer M,Fleck M,Schutz C,et al.PD-L1 is induced in hepatocytes by viral infection and by interferon-a and-g and mediates T cell apoptosis[J].J Hepatol,2006,45:520-528.
    [26]
    Yang W,Chen PW,Li H,et al.PD-L1:PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro[J].Invest Ophthalmol Vis Sci,2008,49(6):2518.
    [27]
    Niwa Y,Kanda H,Shikauchi Y,et al.Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma[J].Oncogene,2005,24:116-119.
    [28]
    Timofeeva OA,Tarasova NI,Zhang X,et al.STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain[J].Proc Natl Acad Sci U S A,2013,110(4):1267-1272.
    [29]
    Choudhari S,Khan M,Harris G,et al.Deactivation of Akt and STAT-3 signaling promotes apoptosis,inhibits proliferation and enhances sensitivity of HCC cells to an anti-cancer agent,Atiprimod[J].Mol Cancer Ther,2007,67:2377-2377.
    [30]
    Chen J,Jiang CC,Jin L,et al.Regulation of PD-L1:a novel role of pro-survival signalling in cancer[J].Ann Oncol,2015,27(3):409-416.
  • Related Articles

    [1]ZHAO Xiujuan, YANG Hengli, WU Jinye, ZHENG Xiaoqi, ZHANG Yaoping, LIN Yuping, HU Chunyan. Synthesis and anti-inflammatory activity of three series of coumarin-based derivatives[J]. Journal of China Pharmaceutical University, 2025, 56(1): 40-48. DOI: 10.11665/j.issn.1000-5048.2024072101
    [2]SHEN Yunhong, CHEN Hongjie, MAO Zewei, HUANG Zhengxiao, HU Chunyan. Synthesis and antifungal evaluation of chalcone derivatives combined with fluconazole against drug-resistant Candida albicans[J]. Journal of China Pharmaceutical University, 2023, 54(5): 564-568. DOI: 10.11665/j.issn.1000-5048.2023041002
    [3]WANG Mengxiao, MA Lingman, LIU Hanhan, JIANG Meiling, DOU Jie, ZHOU Changlin. Effective antimicrobial activity of Cbf-14-2 against penicillin-resistant bacteria in vitro and in vivo[J]. Journal of China Pharmaceutical University, 2017, 48(4): 496-502. DOI: 10.11665/j.issn.1000-5048.20170416
    [4]TANG Yong, LIAO Shengrong, LI Jinsheng, LIU Yonghong. Design, synthesis and cytotoxic activities of fluorine-containing 2, 5-diketopiperazine derivatives[J]. Journal of China Pharmaceutical University, 2016, 47(4): 412-421. DOI: 10.11665/j.issn.1000-5048.20160405
    [5]ZHANG Qian, CHEN Cen, YANG Fengqing, XIA Zhining. Mechanism of agonist-induced platelet activation and research progress of anti-platelet drugs[J]. Journal of China Pharmaceutical University, 2014, 45(6): 632-648. DOI: 10.11665/j.issn.1000-5048.20140604
    [6]LI Bing, LI Bo, ZHOU Changlin. Progress on antimicrobial peptides against drug-resistant bacterial infection[J]. Journal of China Pharmaceutical University, 2014, 45(5): 580-586. DOI: 10.11665/j.issn.1000-5048.20140514
    [7]WU Mingming, FANG Lei, GOU Shaohua, CHEN Li. 以2-甲基-2-取代苯氧基丙酸为离去基团的铂(Ⅱ)配合物的合成、表征及细胞毒活性[J]. Journal of China Pharmaceutical University, 2013, 44(4): 303-306. DOI: 10.11665/j.issn.1000-5048.20130403
    [8]Advances in the research of anti-tuberculosis drugs[J]. Journal of China Pharmaceutical University, 2010, 41(4): 299-305.
    [9]MIAO You-pan, LI Ai-xiu, LIU Tao, WU Ke-zhu. Molecular designing strategies of anti-drug-resistant HIV-1 protease inhibitors[J]. Journal of China Pharmaceutical University, 2009, 40(3): 279-283.
    [10]Structure-Cytotoxic Activity Relationships of Diterpenoid Tanshinones from Salvias[J]. Journal of China Pharmaceutical University, 2002, (1): 8-14.

Catalog

    Article views (843) PDF downloads (1039) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return